Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 11fludarabine phosphate 8Peripheral Blood Stem Cell Transplantation 7Etoposide 7Filgrastim 6Daunorubicin 6Vorinostat 5Specimen Handling 5Decitabine 5Cyclophosphamide 5Busulfan 5Biopsy 5Methotrexate 4Cyclosporine 4venetoclax 3sargramostim 3decitabine and cedazuridine drug combination 3Liposomes 3Injections 3Idarubicin 3CPX-351 3Azacitidine 3tipifarnib 2romidepsin 2pomalidomide 2laromustine 2fludarabine 2Vincristine 2Tretinoin 2Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Myeloproliferative Disorders × iadademstat × Clear all
NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡